Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: Support for the prostate saturation theory

Journal of Urology

Volumn 186, Issue 3, 2011, Pages 1005-1011

  Khera, Mohit ^a   Bhattacharya, Rajib K ^b   Blick, Gary ^c   Kushner, Harvey ^d   Nguyen, Dat ^d   Miner, Martin M ^e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c Circle Medical LLC ^*  (United States)

^d Auxilium Pharmaceuticals   (United States)

^e BROWN UNIVERSITY   (United States)

Author keywords

hormone replacement therapy; prostate specific antigen; testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ANDROGEN THERAPY; ANTIGEN DETECTION; ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE REGISTRY; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE SATURATION THEORY; TESTOSTERONE BLOOD LEVEL; THEORY; THERAPY EFFECT;

ADULT; AGED; AGED, 80 AND OVER; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; TESTOSTERONE; TIME FACTORS;

EID: 80051546083     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.04.065     Document Type: Article

References (28)

1. S. Bhasin, G.R. Cunningham, and F.J. Hayes Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 95 2010 2536
2. C. Wang, E. Nieschlag, and R. Swerdloff Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations Eur Urol 55 2009 121
3. M. Miner, D.J. Canty, and R. Shabsigh Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices Postgrad Med 120 2008 130
4. E. Darby, and B.D. Anawalt Male hypogonadism: an update on diagnosis and treatment Treat Endocrinol 4 2005 293
5. A. Barqawi, and E.D. Crawford Testosterone replacement therapy and the risk of prostate cancer Is there a link? Int J Impot Res 18 2006 323
6. J. Gore, and J. Rajfer Rising PSA during testosterone replacement therapy Rev Urol 6 2004 S41
7. D.C. Gould, and R.S. Kirby Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer? Prostate Cancer Prostatic Dis 9 2006 14
8. C. Wang, E. Nieschlag, and R.S. Swerdloff ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males Aging Male 12 2009 5
9. N.E. Eaton, G.K. Reeves, and P.N. Appleby Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies Br J Cancer 80 1999 930
10. Endogenous Hormones and Prostate Cancer Collaborative Group A.W. Roddam, and N.E. Allen Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies J Natl Cancer Inst 100 2008 170
11. A. Morgentaler Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer J Sex Med 5 2008 1834
12. F.C. Wu, T.M. Farley, and A. Peregoudov Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study World Health Organization Task Force on Methods for the Regulation of Male Fertility Fertil Steril 65 1996 626
13. A. Morgentaler, and A.M. Traish Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth Eur Urol 55 2008 310
14. M. Miner, M. Khera, and R.K. Bhattacharya TESTIM Registry in the United States (TRiUS): baseline demographic and clinical parameters J Sex Med 7 2010 15
15. M. Zitzmann, S. Faber, and E. Nieschlag Association of specific symptoms and metabolic risks with serum testosterone in older men J Clin Endocrinol Metab 91 2006 4335
16. S. Bhasin, T.W. Storer, and N. Berman The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men N Engl J Med 335 1996 1
17. C.S. Cooper, J.H. MacIndoe, and P.J. Perry The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men J Urol 156 1996 438
18. A.W. Meikle, S. Arver, and A.S. Dobs Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system Urology 49 1997 191
19. P.J. Snyder, H. Peachey, and J.A. Berlin Effects of testosterone replacement in hypogonadal men J Clin Endocrinol Metab 85 2000 2670
20. C. Steidle, S. Schwartz, and K. Jacoby AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function J Clin Endocrinol Metab 88 2003 2673
21. S. von Eckardstein, and E. Nieschlag Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study J Androl 23 2002 419
22. L.S. Marks, N.A. Mazer, and E. Mostaghel Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial JAMA 296 2006 2351
23. S. Bhasin, A.B. Singh, and R.P. Mac Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan J Androl 24 2003 299
24. ® 1% testosterone gel in hypogonadal men Rev Urol 7 2005 87
25. C. Wang, G. Cunningham, and A. Dobs Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men J Clin Endocrinol Metab 89 2004 2085
26. S.E. Lee, J.S. Chung, and B.K. Han Relationship of prostate-specific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia Urology 71 2008 395
27. C.G. Roehrborn, P. Boyle, and A.L. Gould Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia Urology 53 1999 581
28. C.G. Roehrborn, J. McConnell, and J. Bonilla Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia PROSCAR long-term efficacy and safety study J Urol 163 2000 13